| |
MDxHealth SA, a world-leading player in the field of molecular diagnostic prostate cancer testing, today announces that it has entered into a commercial service agreement with Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata (IDI), a leading research Hospital in Rome, to provide SelectMDx® for prostate cancer as a service test.
SelectMDx® is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. Under the terms of the agreement, the IDI Laboratory of Clinical Molecular Diagnostics, will perform SelectMDx testing locally by purchasing SelectMDx CE-marked IVD kits from MDxHealth, initially using the MDxHealth Central Lab in Nijmegen, The Netherlands for processing tests.
"We are excited that Istituto Dermopatico Immacolata Hospital is going to offer SelectMDx service testing to assist physicians in identifying patients at increased risk of harbouring aggressive, potentially lethal, prostate cancer" said Dr. Jan Groen, CEO of MDxHealth. "IDI's broad hospital network will significantly contribute to the successful market penetration of SelectMDx in Italy."
"We are delighted to offer this innovative test to our patients," commented Prof. Antonio M. Leozappa, President of Fondazione Luigi Maria Monti - IDI Hospital - Italy. "This partnership reinforces our commitment to provide our oncologists and urologists with a service test facilitating individualized and personalized medicine paths for patients. We believe that utilising state of the art diagnostics such as SelectMDx will allow our hospital to give our patients the best possible care."
About SelectMDx for Prostate Cancer
Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby reducing healthcare costs.
About MDxHealth
MDxHealth (mdxhealth.com) is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.
About IDI
Since 1990 Istituto Dermopatico dell' Immacolata Hospital (idi.it) has been recognized by the Italian Ministry of Research and Health as a Research Hospital. The Hospital has several Research Departments looking after rare dermatological diseases, varying from inflammatory ones, to immune-mediated diseases to skin tumors, being the Reference Centre for whole Lazio Region. The Laboratory Diagnostic Department, following the Hospital strategies and clinical patient needs, as per the efficacy, efficiency and safety criteria, performs lab tests on different biological materials, for health promotion, prevention, diagnosis, prognosis, monitoring and therapeutic surveillance. The laboratory is composed by several units such as biochemistry, allergology, immunology, microbiology, pharmatoxicology, molecular biology and genetics.
Contacts
Dr. Andrea Barbieri - IDI
T: +39 06 66464564 / +39 06 6464454 - E: ufficio.stampa[.]idi.it.
Leon Melens - LifeSpring Life Sciences Communication
T: +31 6 538 16 427 - E: lmelens[.]lifespring.nl.
Amber Fennell / Chris Welsh / Hendrik Thys - Consilium Strategic Communications (IR & PR)
T: +44(0)20 3709 5701 - E: mdxhealth[.]consilium-comms.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
|
info[.]mdxhealth.com 
